AR096789A1 - Derivados de péptidos similares a glp-1 y usos de los mismos - Google Patents

Derivados de péptidos similares a glp-1 y usos de los mismos

Info

Publication number
AR096789A1
AR096789A1 ARP140102467A ARP140102467A AR096789A1 AR 096789 A1 AR096789 A1 AR 096789A1 AR P140102467 A ARP140102467 A AR P140102467A AR P140102467 A ARP140102467 A AR P140102467A AR 096789 A1 AR096789 A1 AR 096789A1
Authority
AR
Argentina
Prior art keywords
derivatives
glp
same
side chains
analogs
Prior art date
Application number
ARP140102467A
Other languages
English (en)
Spanish (es)
Inventor
Wenzel Torne Christian
Reedtz-Runge Steffen
Kofoed Jacob
Sauerberg Per
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of AR096789A1 publication Critical patent/AR096789A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
ARP140102467A 2013-07-04 2014-07-02 Derivados de péptidos similares a glp-1 y usos de los mismos AR096789A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13175094 2013-07-04

Publications (1)

Publication Number Publication Date
AR096789A1 true AR096789A1 (es) 2016-02-03

Family

ID=48703344

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102467A AR096789A1 (es) 2013-07-04 2014-07-02 Derivados de péptidos similares a glp-1 y usos de los mismos

Country Status (11)

Country Link
US (2) US9498534B2 (enExample)
EP (1) EP3016975B1 (enExample)
JP (2) JP6139712B2 (enExample)
KR (1) KR20160029079A (enExample)
CN (1) CN105377884B (enExample)
AR (1) AR096789A1 (enExample)
AU (1) AU2014286234A1 (enExample)
BR (1) BR112015032875A2 (enExample)
CA (1) CA2916311A1 (enExample)
MX (1) MX2015016875A (enExample)
WO (1) WO2015000942A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3010546B1 (en) 2013-06-20 2017-08-09 Novo Nordisk A/S Glp-1 derivatives and uses thereof
BR112015032875A2 (pt) * 2013-07-04 2017-11-07 Novo Nordisk As derivados de peptídeos do tipo glp-1, e usos dos mesmos
JP6730278B2 (ja) 2014-11-27 2020-07-29 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
US10392428B2 (en) 2014-12-17 2019-08-27 Novo Nordisk A/S GLP-1 derivatives and uses thereof
HK1252425A1 (zh) 2015-06-05 2019-05-24 Vertex Pharmaceuticals Incorporated 用於治疗脱髓鞘疾病的三唑类药物
PL3393496T3 (pl) 2015-12-23 2024-04-22 The Johns Hopkins University Długo działający agonista glp-1r jako terapia stanów neurologicznych i neurodegeneracyjnych
ES2835033T3 (es) 2016-03-03 2021-06-21 Novo Nordisk As Derivados de GLP-1 y sus usos
MA46780A (fr) 2016-11-07 2019-09-11 Novo Nordisk As Esters à dchbs actif de composés peg et leur utilisation
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
CN108976147B (zh) * 2017-05-31 2021-02-12 首都医科大学 氨基正己酰氨基甲环酰氨基正己酰碱性氨基酸，其合成，活性和应用
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
EP3655427A1 (en) 2017-07-19 2020-05-27 Novo Nordisk A/S Bifunctional compounds
TWI847306B (zh) 2017-08-24 2024-07-01 丹麥商諾佛 儂迪克股份有限公司 Ｇｌｐ-１組成物及其用途
JP7359358B2 (ja) * 2017-11-30 2023-10-11 グリアファーム エスエー 神経疾患の予防及び治療に使用するためのポリケチド化合物及びその誘導体
ES2980707T3 (es) 2018-04-05 2024-10-02 Sun Pharmaceutical Ind Ltd Nuevos análogos de GLP-1
CN115814063A (zh) * 2018-04-19 2023-03-21 杭州先为达生物科技有限公司 Glp-1衍生物及其治疗用途
WO2019200594A1 (zh) 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
CN110386975B (zh) * 2018-04-19 2021-06-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
JP6984753B2 (ja) * 2018-07-12 2021-12-22 三菱電機株式会社 半導体装置
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
CN115322794B (zh) 2020-01-11 2025-09-19 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
BR112022013795A2 (pt) 2020-02-18 2022-09-13 Novo Nordisk As Composição farmacêutica líquida, e, kit
JP2023545684A (ja) 2020-09-30 2023-10-31 ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド ポリペプチドコンジュゲートおよび使用の方法
CN114685644A (zh) * 2020-12-29 2022-07-01 苏州康宁杰瑞生物科技有限公司 一种人glp-1多肽变体及其应用
CA3224743A1 (en) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders
EP4323413A4 (en) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
AU2023415591A1 (en) 2022-12-30 2025-08-14 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO1999043706A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
PL351326A1 (en) 1999-03-17 2003-04-07 Novo Nordisk As Method for acylating peptides and novel acylating agents
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
EP1239871A1 (en) 1999-11-12 2002-09-18 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration
GB0020551D0 (en) 2000-08-22 2000-10-11 Birkett David Sprinkler system
EA009366B1 (ru) 2003-03-19 2007-12-28 Эли Лилли Энд Компани Связанные с полиэтиленгликолем соединения гпп-1
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
KR101011081B1 (ko) 2005-05-13 2011-01-25 일라이 릴리 앤드 캄파니 Ｐｅｇ화된 ｇｌｐ-1 화합물
EP2164466A1 (en) 2007-06-01 2010-03-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
ES2672770T3 (es) 2007-09-05 2018-06-18 Novo Nordisk A/S Derivados del péptido-1 similar al glucagón y su uso farmacéutico
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
JP2012518029A (ja) 2009-02-19 2012-08-09 ノヴォ・ノルディスク・アー／エス 第ｖｉｉｉ因子の修飾
CN104327182B (zh) 2009-12-16 2020-04-17 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
CN105601729A (zh) 2010-11-09 2016-05-25 诺沃—诺迪斯克有限公司 双-酰化的glp-1衍生物
KR101972836B1 (ko) 2011-04-12 2019-04-29 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
BR112015032875A2 (pt) * 2013-07-04 2017-11-07 Novo Nordisk As derivados de peptídeos do tipo glp-1, e usos dos mesmos

Also Published As

Publication number Publication date
US10010614B2 (en) 2018-07-03
BR112015032875A2 (pt) 2017-11-07
JP6139712B2 (ja) 2017-05-31
KR20160029079A (ko) 2016-03-14
CN105377884B (zh) 2021-07-20
MX2015016875A (es) 2016-04-07
US9498534B2 (en) 2016-11-22
CN105377884A (zh) 2016-03-02
JP2016528163A (ja) 2016-09-15
AU2014286234A1 (en) 2015-12-17
JP2017105819A (ja) 2017-06-15
EP3016975B1 (en) 2019-01-16
JP6687557B2 (ja) 2020-04-22
US20170007707A1 (en) 2017-01-12
WO2015000942A1 (en) 2015-01-08
EP3016975A1 (en) 2016-05-11
US20150011462A1 (en) 2015-01-08
CA2916311A1 (en) 2015-01-08

Similar Documents

Publication Publication Date Title
AR096789A1 (es) Derivados de péptidos similares a glp-1 y usos de los mismos
CO2020003478A2 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
MX2015016564A (es) Derivados de peptido similar al glucaton tipo 1 (glp-1) y uso de los mismos.
MX392572B (es) Compuestos del péptido yy (pyy) selectivos y sus usos.
MY181181A (en) Fgf21 derivatives and uses thereof
GT201500049A (es) Proteinas de fusiòn para el tratamiento de un sìndrome metàbolico
ECSP19021223A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CR20160006A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
UY37505A (es) Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico
MX2018015252A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
BR112017012342A2 (pt) compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos
BR112018012707A2 (pt) inibidores da interação de menin-mll
UY36186A (es) Ácidos grasos novedosos y su uso en la conjugación con biomoléculas
CR20160237A (es) Derivados de la carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
HRP20190388T1 (hr) Eksendin-4 derivati kao peptidni dvostruki agonisti receptora glp-1 / glukagona
PE20180449A1 (es) Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo
CR20170129A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico
MX2016001971A (es) Composiciones farmaceuticas parenterales acuosas estables de peptidos insulinotropicos.
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
CO2017006898A2 (es) Formulación de relación fija de insulina glargina/lixisenatida
AR095527A1 (es) Formulaciones de polipéptido fc-factor ix
BR112017021190A2 (pt) composição farmacêutica e o uso da mesma
EA201790495A1 (ru) Фармацевтические композиции длительного действия
CY1122935T1 (el) Ενισχυτικα της υδατοδιαλυτοτητας που βασιζονται στο γλυκογονο

Legal Events

Date Code Title Description
FB Suspension of granting procedure